Lexicon Pharmaceuticals, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Lexicon Pharmaceuticals, Inc. - overview
Established
1995
Location
The Woodlands, TX, US
Primary Industry
Biotechnology
About
Founded in 1995 by Allan Bradley and Arthur T. Sands, and based in Texas, US, Lexicon Pharmaceuticals, Inc. , formerly Lexicon Genetic operates as a biopharmaceutical company and uses gene science to discover and develop medicines for people with chronic conditions. The firm trades on the NASDAQ under the ticker symbol, LXRX.
In March 2024, Invus, Great Point Partners, OrbiMed Advisors, and Braidwell invested approximately USD 250 million in Lexicon Pharmaceuticals, Inc. Lexicon Pharmaceuticals' product line includes INPEFA® (sotagliflozin), a once-daily oral tablet for reducing the risk of cardiovascular death and hospitalization in adults with heart failure or those with type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors. The firm also develops and offers other therapeutic candidates, including LX9211 for neuropathic pain. Lexicon's pipeline focuses on innovative therapies for diseases like heart failure and neuropathic pain, leveraging their expertise in gene science to advance treatments that address significant unmet medical needs.
The company intends to use the March 2024 investment to accelerate the development of its platform offerings.
Current Investors
Invus [DUP], Artal International, BVF Partners
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy
Website
www.lexpharma.com
Verticals
Manufacturing
Company Stage
Mature
Total Amount Raised
Subscriber access only
Lexicon Pharmaceuticals, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PIPE | Completed | Lexicon Pharmaceuticals, Inc. | - | ||||||||
| Private Placement/Follow on | Completed | Lexicon Pharmaceuticals, Inc. | - | ||||||||
| PIPE | Completed | Lexicon Pharmaceuticals, Inc. | - | ||||||||
| PIPE | Completed | Lexicon Pharmaceuticals, Inc. | - | ||||||||
| Private Placement/Follow on | Completed | Lexicon Pharmaceuticals, Inc. | - |
Displaying 1 - 5 of 13
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.